APP
SLNO

Avantax Planning Partners’s Soleno Therapeutics SLNO Stock Holding History

Avantax Planning Partners’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-713
Closed -$2K – 362
2022
Q2 		$2K Hold
713
– – ﹤0.01% 343
2022
Q1 		$2K Hold
713
– – ﹤0.01% 359
2021
Q4 		$4K Hold
713
– – ﹤0.01% 355
2021
Q3 		$10K Hold
713
– – ﹤0.01% 339
2021
Q2 		$12K Hold
713
– – ﹤0.01% 326
2021
Q1 		$13K Buy
+713
New +$23K ﹤0.01% 314

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
CP
Clayton Partners Berkeley, California $138M AUM 38.58% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Avantax Planning Partners's SLNO Position: Q3 2022 in Review

Avantax Planning Partners sold out of Soleno Therapeutics (SLNO) in Q3 2022, closing a stake of 713 shares — an estimated $2K sold.

Avantax Planning Partners first reported a position in SLNO in Q1 2021 and held it in 6 quarters. The position peaked at $13K in Q1 2021. 22 funds tracked by Wall St. Rank hold SLNO as of Q3 2022.

  • Avantax Planning Partners reported no remaining Soleno Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Avantax Planning Partners sold 713 Soleno Therapeutics shares in Q3 2022, an estimated $2K.
  • Avantax Planning Partners first reported a position in Soleno Therapeutics in Q1 2021 and held it in 6 quarters.
  • Avantax Planning Partners's Soleno Therapeutics position peaked at $13K in Q1 2021.
  • 22 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2022.

Based on Avantax Planning Partners's 13F filing for Q3 2022, filed 14 Oct 2022.